磁共振成像靶向前列腺穿刺确诊患者中侧别系统性穿刺的附加价值
研究基于15个欧洲转诊中心2016年1月至2023年4月的前瞻性数据库,纳入2387例接受MRI靶向联合系统穿刺、PI-RADS评分≥3的患者,比较不同穿刺策略对临床显著前列腺癌(csPCa)的检出率,并外部验证Noujeim风险分层模型。结果显示对侧系统穿刺的附加价值可忽略,Noujeim模型区分度中等(AUC 0.63)。
要点
- 以MRI靶向穿刺为参照,系统穿刺、同侧系统穿刺和对侧系统穿刺对csPCa检出的附加价值分别为5.8%、4.2%和2.8%。
- 仅35例(1.5%)患者单独通过对侧系统穿刺检出csPCa(p < 0.001)。
- 在MRI靶向穿刺和同侧系统穿刺已检出csPCa的患者中,对侧系统穿刺带来的升级率为2%(20/961,p < 0.001)。
核心结论
- 对侧系统穿刺在癌症检出率和升级率方面的附加价值可忽略。
- Noujeim模型可纳入关于合适前列腺穿刺策略的决策过程。
研究设计与样本
- 研究为基于前瞻性维护数据库的分析,纳入2016年1月至2023年4月15个欧洲转诊中心的4841例连续患者,其中2387例符合纳入标准并进入分析。
- 患者均因PI-RADS评分≥3的病灶接受MRI靶向穿刺和系统穿刺。
- 采用McNemar检验比较MRI靶向穿刺、侧别系统穿刺及两者联合等策略的csPCa检出率。
- 模型性能通过受试者工作特征曲线下面积(AUC)、校准图和决策曲线分析评估。
- 临床显著前列腺癌定义为国际泌尿病理学会分级分组≥2。
主要发现
- 总体csPCa检出率为49%。
- 以MRI靶向穿刺为参照,系统穿刺、同侧系统穿刺和对侧系统穿刺对csPCa检出的附加价值分别为5.8%(相对增加13%)、4.2%(相对增加9.8%)和2.8%(相对增加6.1%)。
- 仅35例(1.5%)患者单独通过对侧系统穿刺检出csPCa(p < 0.001)。
- 在MRI靶向穿刺和同侧系统穿刺已检出csPCa的患者中,使用对侧系统穿刺的升级率为2%(20/961,p < 0.001)。
- Noujeim模型在外部验证集中区分度中等(AUC 0.63)。
临床怎么用
- 作者认为对侧系统穿刺在癌症检出和升级方面的附加价值可忽略。
- 作者认为Noujeim模型可纳入关于合适前列腺穿刺策略的决策过程。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Systematic biopsy (SB) combined with magnetic resonance imaging (MRI)-targeted biopsy is still recommended considering the risk of missing clinically significant prostate cancer (csPCa). OBJECTIVE: To evaluate the added value in csPCa detection on side-specific SB relative to MRI lesion and to externally validate the Noujeim risk stratification model that predicts the risk of csPCa on distant SB cores relative to the index MRI lesion. DESIGN, SETTING, AND PARTICIPANTS: Overall, 4841 consecutive patients diagnosed by MRI-targeted biopsy and SB for Prostate Imaging Reporting and Data System score ≥3 lesions were identified from a prospectively maintained database between January 2016 and April 2023 at 15 European referral centers. A total of 2387 patients met the inclusion criteria and were included in the analysis. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: McNemar's test was used to compare the csPCa detection rate between several biopsy strategies including MRI-targeted biopsy, side-specific SB, and a combination of both. Model performance was evaluated in terms of discrimination using area under the receiver operation characteristic curve (AUC), calibration plots, and decision curve analysis. Clinically significant prostate cancer was defined as International Society of Urological Pathology grade group ≥2. RESULTS AND LIMITATIONS: Overall, the csPCa detection rate was 49%. Considering MRI-targeted biopsy as reference, the added values in terms of csPCa detection were 5.8% (relative increase of 13%), 4.2% (relative increase of 9.8%), and 2.8% (relative increase of 6.1%) for SB, ipsilateral SB, and contralateral SB, respectively. Only 35 patients (1.5%) exclusively had csPCa on contralateral SB (p < 0.001). Considering patients with csPCa on MRI-targeted biopsy and ipsilateral SB, the upgrading rate was 2% (20/961) using contralateral SB (p < 0.001). The Noujeim model exhibited modest performance (AUC of 0.63) when tested using our validation set. CONCLUSIONS: The added value of contralateral SB was negligible in terms of cancer detection and upgrading rates. The Noujeim model could be included in the decision-making process regarding the appropriate prostate biopsy strategy. PATIENT SUMMARY: In the present study, we collected a set of patients who underwent magnetic resonance imaging (MRI)-targeted and systematic biopsies for the detection of prostate cancer. We found that biopsies taken at the opposite side of the MRI suspicious lesion have a negligible impact on cancer detection. We also validate a risk stratification model that predicts the risk of cancer on biopsies beyond 10 mm from the initial lesion, which could be used in daily practice to improve the personalization of the prostate biopsy.
引用
- Bourgeno HA, Jabbour T, Baudewyns A, et al. The Added Value of Side-specific Systematic Biopsy in Patients Diagnosed by Magnetic Resonance Imaging-targeted Prostate Biopsy. Eur Urol Oncol. 2024. PMID: 38272745. doi:10.1016/j.euo.2024.01.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。